REG-Bioventix Plc: Posting of Annual Report and Notice of AGM

BioventixAnnouncement

16/11/2020 14:20

Bioventix plc
(“Bioventix” or the “Company”)

Posting of Annual Report and Notice of AGM

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, and development company confirms that its Annual Report
and Accounts for the year ended 30 June 2020 and the Notice of Annual General
Meeting (“AGM”) has been posted to shareholders.

These documents are available on the Company's website at www.bioventix.com.

The AGM will be held electronically at 2.00 p.m. on 10 December 2020.

As a result of the current UK Government guidance on social distancing and
prohibiting public gathering over certain numbers, the Company has taken the
decision that this year unfortunately it will not be possible for shareholders
to attend the AGM.

Details on how shareholders can vote by proxy are set out in the Notice of
Annual General Meeting. The Company therefore requests that shareholders
appoint the Chairman of the meeting as a proxy and provide their voting
responses in advance of the AGM.
 

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
                                                                                             
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved